In a recent feature published by Inserm, IRCAN Director Dmitry Bulavin describes his team’s latest research on disease tolerance, an emerging concept in immunology.

In the article, he explains how the body can respond to infection not only by eliminating pathogens, but also by limiting the damage they cause to tissues. This complementary mechanism may play an important role in improving outcomes during severe inflammatory responses.

Dmitry highlights the role of a specific population of immune cells, known as p16High cells, which help regulate inflammation and support tissue protection. His work shows that increasing these cells can improve survival under conditions of severe stress.

He also discusses findings showing that mRNA vaccines can activate this pathway, promoting the expansion of these protective cells through TLR7 signalling. This suggests a broader role for such vaccines in supporting immune resilience.

This research aligns closely with IRCAN’s focus on ageing, particularly in understanding how to maintain tissue function and reduce the impact of chronic inflammation over time.

🔗 Read the full Inserm article:
https://presse.inserm.fr/la-tolerance-aux-maladies-une-nouvelle-strategie-de-defense-activee-par-les-vaccins-a-arnm-revelee/72430/